Article
Oncology
Petra Muus, Saskia Langemeijer, Sandra van Bijnen, Nicole Blijlevens, Theo de Witte
Summary: The combination of tipifarnib and bortezomib showed good tolerability and clinical activity in patients with high-risk MDS and oligoblastic AML. Some patients achieved complete responses or stable disease, with a median overall survival of 449 days. Further evaluation in a phase II study is warranted based on these results.
Article
Oncology
Uwe Platzbecker, Joerg Chromik, Jan Kroenke, Hiroshi Handa, Stephen Strickland, Yasushi Miyazaki, Martin Wermke, Wataru Sakamoto, Yoshifumi Tachibana, Tillmann Taube, Ulrich Germing
Summary: This report summarizes three phase I studies evaluating the efficacy of volasertib, a polo-like kinase inhibitor, plus azacitidine in adult patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. The studies showed that the combination treatment was well-tolerated and showed preliminary activity in patients with myelodysplastic syndromes.
Article
Oncology
Courtney D. DiNardo, Andreas Hochhaus, Mark G. Frattini, Karen Yee, Thomas Zander, Alwin Kraemer, Xueying Chen, Yan Ji, Nehal S. Parikh, Joanne Choi, Andrew H. Wei
Summary: This study aimed to determine the recommended dose for IDH305 in patients with IDH1(R132)-mutant AML and MDS. The results showed acceptable pharmacokinetic characteristics of IDH305 in patients, and demonstrated target engagement. Although adverse events were reported, hepatotoxicity could be managed through dose modification.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Medicinal
Hana Votavova, Zuzana Urbanova, David Kundrat, Michaela Dostalova Merkerova, Martin Vostry, Monika Hruba, Jaroslav Cermak, Monika Belickova
Summary: DFX improves hematopoiesis in anemic myelodysplastic syndrome patients by modulating immune response, suppressing negative regulators of blood cell differentiation, and upregulating heme metabolism.
Letter
Oncology
Tao Zhang, Paul Auer, Jing Dong, Corey Cutler, Amy E. Dezern, Shahinaz M. Gadalla, H. Joachim Deeg, Aziz Nazha, Karen-Sue Carlson, Stephen Spellman, Yung-Tsi Bolon, Wael Saber
Summary: Through whole-genome sequencing, we identified 12 novel regions and 3 molecular signatures that are significantly associated with overall survival in myelodysplastic syndromes (MDS). We also discovered two novel gene mutations, CHD1 and DDX11, which have a negative impact on survival in AML/MDS and lymphoid cancer data. Furthermore, we identified additional molecular signatures related to MDS through both unsupervised and supervised clustering. By combining genomic candidates, subgroups, and clinical variables, our prognostic model achieved superior performance compared to models using only clinical variables.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Cristiano Luiz Ribeiro, Irene P. Pinto, Samara S. S. Pereira, Lysa B. Minasi, Fernanda de S. M. Kluthcouski, Adriano de M. Arantes, Aparecido D. Cruz, Marcio A. A. de Almeida, Tom E. Howard, Claudio C. da Silva
Summary: In this study, Chromosomal Microarray Analysis (CMA) was conducted on primary MDS patients without visible chromosomal alterations in their karyotypes, revealing genetic changes associated with abnormal cell differentiation. These alterations in specific genes may contribute to the malignization of MDS, providing additional information for prognosis and personalized patient stratification.
SCIENTIFIC REPORTS
(2021)
Letter
Oncology
Xin Huang, Cunte Chen, Mengjun Zhong, Suxia Geng, Yujie Zhao, Minming Li, Chenxin Deng, Lingji Zeng, Ping Wu, Zesheng Lu, Jianyu Weng, Xin Du, Yangqiu Li
Summary: The study showed that lower expression of BCL11B in BM samples of MDS patients is associated with adverse clinical outcomes. Low BCL11B expression appears to be linked to poor overall survival, especially for high-risk MDS patients.
BIOMARKER RESEARCH
(2021)
Article
Energy & Fuels
Gregory Vinicius Bezerra de Oliveira, Jefferson David Coutinho de Araujo, Maria Clara de Meneses Lourenco, Ana Paula Teixeira Araujo de Freitas, Marcos Allyson Felipe Rodrigues, Tereza Neuma de Castro Dantas, Alcides de Oliveira Wanderley Neto, Daniel Alberton Haas
Summary: Steam injection is commonly used for enhanced oil recovery in heavy oil fields, but its efficiency declines in later stages. This study proposes an innovative method by alternating steam and microemulsion injection to optimize heavy oil recovery in sandstone reservoirs. Three microemulsions with varying surfactant concentrations were produced and assessed for their viscosity, stability, surface tension, and interfacial tension. The results showed that the alternated injection achieved higher recovery factors compared to steam injection alone, due to the combined effects of viscosity reduction, interfacial tension decrease, and alteration of rock wettability. This study demonstrates the potential of steam and microemulsion alternated injection as an effective approach for enhanced heavy oil recovery.
Review
Immunology
Likun Zheng, Lei Zhang, Yixuan Guo, Xintong Xu, Zhaoyun Liu, Zhenyu Yan, Rong Fu
Summary: Myelodysplastic syndrome (MDS) is a common hematological malignant disease characterized by abnormal proliferation of malignant hematopoietic stem cells in the bone marrow. The dysfunction of mesenchymal stromal cells (MSCs) in the bone marrow microenvironment plays a critical role in MDS progression through modulation of immune cell function, enabling evasion of immune surveillance by MDS-associated malignant cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep Dave, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Dipankar Bandyopadhyay, Caryn Weir, Elizabeth B. Collins, Amanda Garnett, Maciej Kmieciak, John D. Roberts, Guillermo Garcia-Manero, Steven Grant
Summary: This study reports the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia and myelodysplastic syndrome. The treatment strategy showed limited activity in the population studied, but some patients exhibited good responses, indicating the need for further investigation into predictive factors for exceptional responses.
LEUKEMIA & LYMPHOMA
(2021)
Article
Medicine, General & Internal
Martin Bauer, Edith Lackner, Peter Matzneller, Valentin Al Jalali, Sahra Pajenda, Vincent Ling, Christof Bohler, Werner Braun, Reinhard Braun, Maximilian Boesch, Patrick M. Brunner, Markus Zeitlinger
Summary: This study investigated the safety and tolerability of ablative fractional laser treatment in patients with plaque-type psoriasis, showing a favorable safety profile. Topical administration of ETA to psoriatic plaques via AFL-generated micropores was generally well-tolerated.
FRONTIERS IN MEDICINE
(2021)
Article
Clinical Neurology
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, Yasuo Haruyama, Hiroaki Fujita, Kei Funakoshi, Koichi Hirata
Summary: This study retrospectively assessed the effect of galcanezumab in the first week after administration and found that it had a significant effect. The number of weekly migraine days and monthly migraine days significantly improved after 1-3 months of treatment. Additionally, the response rate at week 1 could predict the response rate at 3 months.
JOURNAL OF NEUROLOGY
(2023)
Article
Oncology
Liya Ma, Bin Liang, Huixian Hu, Wenli Yang, Shengyun Lin, Lihong Cao, Kongfei Li, Yuemin Kuang, Lihong Shou, Weimei Jin, Jianping Lan, Xingnong Ye, Jing Le, Huyi Lei, Jiaping Fu, Ying Lin, Wenhua Jiang, Zhiying Zheng, Songfu Jiang, Lijuan Fu, Chuanyong Su, XiuFeng Yin, Lixia Liu, Jiayue Qin, Jie Jin, Shenxian Qian, Guifang Ouyang, Hongyan Tong
Summary: By reviewing 140 MDS patients with SF3B1 mutation, researchers have developed a personalized prediction model that can better predict the survival of these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jin Qian, Jing Wang, Feng Cheng, Hong-feng Guo, Jun Xia, Xin Zhou
Summary: The prognostic value of the controlling nutritional status score (CONUT) in patients with myelodysplastic syndrome (MDS) was evaluated. The results showed that high CONUT score was significantly associated with low hemoglobin levels and indicated poor overall survival. Thrombocytopenia, high CONUT score, and medium and high risk IPSS-R score were identified as independent prognostic factors in MDS patients.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Hematology
Thibault Comont, Mael Heiblig, Etienne Riviere, Louis Terriou, Julien Rossignol, Didier Bouscary, Virginie Rieu, Guillaume Le Guenno, Alexis Mathian, Achille Aouba, Julien Vinit, Jeremie Dion, Olivier Kosmider, Benjamin Terrier, Sophie Georgin-Lavialle, Pierre Fenaux, Arsene Mekinian
Summary: Azacitidine may be effective in MDS associated with inflammatory/autoimmune diseases. A study on 116 VEXAS patients in France found that azacitidine treatment achieved clinical response in 46% of patients, suggesting its potential effectiveness in selected VEXAS patients with MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Summary: The FDA has an accelerated approval program for potentially promising drugs in treating serious conditions. All available treatments for chronic myeloid leukemia (CML) have undergone this program. A group consisting of CML experts, patient panelists, and FDA members gathered to discuss the utility of the accelerated approval program in CML and its future role in drug development, and the results are summarized here.
CLINICAL CANCER RESEARCH
(2023)
Article
Pathology
Yahya A. Al-Ghamdi, Jonathan Lake, Adam Bagg, Beenu Thakral, Sa A. Wang, Carlos Bueso-Ramos, Lucia Masarova, Srdan Verstovsek, Heesun J. Rogers, Eric D. Hsi, Jonathon H. Gralewski, Devon Chabot-Richards, Tracy I. George, Anton Rets, Robert P. Hasserjian, Olga K. Weinberg, Megan Parilla, Daniel A. Arber, Osvaldo Padilla, Attilio Orazi, Wayne Tam
Summary: This study compared the pathological and genetic characteristics between triple-negative primary myelofibrosis (TN-PMF) and PMF with canonical driver mutations (DM-PMF). The results showed that TN-PMF patients were more likely to have thrombocytopenia and less likely to have organomegaly. The bone marrow of TN-PMF patients showed fewer granulocytic elements and more frequent dyserythropoiesis. Cytogenetic analysis revealed a higher incidence of trisomy 8, and targeted next-generation sequencing identified a lower frequency of ASXL1 mutations but enrichment of ASXL1/SRSF2 comutations. These findings suggest that TN-PMF may be pathogenetically different from DM-PMF, with potential prognostic implications.
Article
Urology & Nephrology
Camilo Montero, Nancy Yomayusa, Rodolfo Torres, Jorge Cortes, Carlos Alvarez, Juan Gallo, Guillermo Aldana, Andres Acevedo, Maria Rios, Johana Echeverri, Zuly Yepes, Adriana Silva, Diana Gayon, Jorge Perez, Milciades Ibanez
Summary: This study aimed to evaluate asymptomatic CMV reactivation and CMV disease in kidney transplant recipients with positive CMV serostatus. The results showed that asymptomatic CMV reactivation was higher in patients who received thymoglobulin induction, while the rates of CMV disease were similar between the two treatment groups. The significant difference in asymptomatic CMV reactivation between the two groups did not affect graft function and histology.
Article
Oncology
Michael J. Mauro, Timothy P. Hughes, Dong-Wook Kim, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gomez-Garcia de Soria, Philipp le Coutre, Francois-Xavier Mahon, Jeroen J. W. M. Janssen, Michael Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang
Summary: Asciminib has been approved for patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) who have received >= 2 prior tyrosine kinase inhibitors or have the T315I mutation. A phase 1 trial evaluated the safety and efficacy of asciminib monotherapy in 115 CML-CP patients without T315I. After a median exposure of approximately 4 years, most patients remained on asciminib and achieved significant molecular responses.
Review
Hematology
Rodrick Babakhanlou, Srdan Verstovsek, Naveen Pemmaraju, Cristhiam M. M. Rojas-Hernandez
Summary: Erythrocytosis is characterized by elevated hemoglobin and hematocrit levels. It can be classified as primary or secondary, with primary erythrocytosis resulting from a clonal disorder in the bone marrow and secondary erythrocytosis being caused by external stimuli. This review focuses on secondary erythrocytosis, discussing its causes, clinical presentation, and diagnostic and therapeutic approaches.
EXPERT REVIEW OF HEMATOLOGY
(2023)
Article
Oncology
Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean-Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke, Srdan Verstovsek
Summary: This study evaluated the longitudinal change in total symptom score (TSS) and individual symptom scores in MF patients receiving therapy, and found that momelotinib provided clinically relevant symptom benefits compared to control group.
Article
Virology
Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K. Mondal, Kimya Jones, Jaspreet Farmaha, Ryan Bloomquist, Caroline Marie Carlock, Drew Fransoso, Christina Sun, Tyler Day, Comfort Prah, Trinh Vuong, Patty Ray, Danielle Bradshaw, Marisol Miranda Galvis, Sadanand Fulzele, Girindra Raval, Justin Xavier Moore, Jorge Cortes, Jeffrey N. James, Vamsi Kota, Ravindra Kolhe
Summary: This study aimed to investigate the temporal changes in the humoral immune response among healthcare workers in Augusta, GA, USA, and explore any associations with ethno-demographic features. The findings showed a significant decline in neutralizing antibody (NAb) and IgG levels at 8-12 months post-vaccination, with a more pronounced decline in White HCWs. Booster doses were found to increase antibody levels significantly, while participants without booster doses experienced a decline in antibody levels at 12 months post-vaccination.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Hematology
Aaron T. Gerds, Srdan Verstovsek, Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C. Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung-Soo Yoon, Vikas Gupta, Jean-Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N. Harrison, Stephen Oh, Barbara J. Klencke, Jing Yu, Rafe Donahue, Jun Kawashima, Ruben Mesa
Summary: The MOMENTUM study demonstrates the durable benefits of momelotinib in patients with myelofibrosis, including symptom, spleen, and anaemia improvements. The study also shows late responses after 24 weeks of treatment and favorable safety profile up to 48 weeks. These findings highlight the potential of momelotinib as a treatment option for myelofibrosis patients.
LANCET HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Srdan Verstovsek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T. Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela C. Lazaroiu, Miklos Egyed, Maria Laura Fox, Donal McLornan, Andrew Perkins, Sung -Soo Yoon, Vikas Gupta, Jean -Jacques Kiladjian, Nikki Granacher, Sung-Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire N. Harrison, Barbara J. Klencke, Sunhee Ro, Rafe Donahue, Jun Kawashima, Ruben Mesa
Summary: This study aimed to compare the clinical effects of momelotinib and danazol in patients with intermediate or high-risk myelofibrosis. The results showed that momelotinib can significantly improve myelofibrosis-associated symptoms, anemia measures, and spleen response compared to danazol, with favorable safety.
Review
Oncology
Rodrick Babakhanlou, Lucia Masarova, Srdan Verstovsek
Summary: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by increased platelet count and excessive megakaryopoiesis. While one-third of cases are benign, the remaining cases can lead to complications such as thromboembolism, hemorrhage, and transformation into aggressive myeloid neoplasms. Limited data exist regarding the management of complications and emergencies associated with ET, despite extensive research on its pathogenesis and etiology. This article focuses on discussing the complications, emergencies, treatment options, and controversies related to the management of ET.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY
(2023)
Meeting Abstract
Hematology
Gemma Shay, Michael W. Deininger, Tim H. Bruemmendorf, Jeffrey H. Lipton, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Meeting Abstract
Oncology
Richard F. Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Muhannad Sharara, Kellen Cristine Tjioe, Marisol Miranda Galvis, Gagan Agrawal, Andrew Balas, Jorge Cortes
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Ana Toreli, Marisol Miranda-Galvis, Marcelo Addas-Carvalho, Eliana Miranda, Leonardo Fechio, Adriana Duarte, Audrey Basso, Gislaine Duarte, Samuel Medina, Fernando Pericole, Bruno Benites, Ravindra Kolhe, Kimya Jones, Harmanpreet Singh, Sara Teresinha Olalla Saad, Carmino Antonio de Souza, Jorge Cortes, Katia Pagnano
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Mark J. Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C. N. Chang, James Hanyok, Li Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)